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For accurate diagnosis, prediction of outcome, and se-
lection of appropriate therapies, the molecular charac-
terization of human diseases requires analysis of a
broad spectrum of altered biomolecules, in addition to
morphological features, in affected tissues such as tu-
mors. In a high-throughput screening approach, we
have developed the PAXgene Tissue System as a novel
tissue stabilization technology. Comprehensive char-
acterization of this technology in stabilized and par-
affin-embedded human tissues and comparison with
snap-frozen tissues revealed excellent preservation of
morphology and antigenicity, as well as outstanding
integrity of nucleic acids (genomic DNA, miRNA, and
mRNA) and phosphoproteins. Importantly, PAXgene-
fixed, paraffin-embedded tissues provided RNA quan-
tity and quality not only significantly better than that
obtained with neutral buffered formalin, but also sim-
ilar to that from snap-frozen tissue, which currently
represents the gold standard for molecular analyses.
The PAXgene tissue stabilization system thus opens
new opportunities in a variety of molecular diagnos-
tic and research applications in which the collection
of snap-frozen tissue is not feasible for medical, logis-
tic, or ethical reasons. Furthermore, this technology
allows performing histopathological analyses to-
gether with molecular studies in a single sample,
which markedly facilitates direct correlation of mor-
458phological disease phenotypes with alterations of nu-
cleic acids and other biomolecules. (J Mol Diagn 2012,
14:458–466; http://dx.doi.org/10.1016/j.jmoldx.2012.05.002)
Significant advances in genomic and proteomic technol-
ogies have provided detailed insight into the diversity of
human diseases. Consequently, diagnosis of diseases
relies more and more on the evaluation of a diversity of
parameters both by means of classical diagnostic tech-
niques such as histopathology and by analysis of a broad
spectrum of biomolecules for genomic alterations, dereg-
ulated gene expression, or protein modifications.1 To ex-
ploit the full capacities of the latest analytical technolo-
gies, excellent preservation of biomolecules in biological
samples is required. The quality of biological samples
analyzed ultimately determines the quality of any analysis
performed with these samples.2 However, the availability
of fresh-frozen tissue, which represents the best material
for molecular analyses, is very limited. Furthermore, the
additional collection of fresh-frozen tissue samples is not
feasible in several disease conditions, such as small tu-
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research and routine applications or for different preana-
lytical procedures. Fixation of tissues in buffered formal-
dehyde solution (formalin) and embedding in paraffin is
the gold standard for processing tissues for histopatho-
logical diagnosis.3 However, because of chemical mod-
ification of biomolecules by formaldehyde (eg, formation
of methylol adducts, Schiff bases, and methylene
bridges), formalin-fixed, paraffin-embedded (FFPE) tis-
sue is of limited use for analyses using modern -omics
technologies.4–6 Although DNA, mRNA, miRNA, and
even proteins can be extracted from FFPE tissues, the
yield and quality of biomolecules is far inferior to those
from fresh, snap-frozen tissues.
There have been several attempts to replace formalde-
hyde by other fixatives, in order to improve the preservation
of biomolecules and to reduce exposure of medical profes-
sionals to potentially carcinogenic formaldehyde.7–15 De-
spite certain advantages, however, the utility of available
tissue preservation techniques for achieving high-quality
results in classical histopathological evaluation, immuno-
histochemistry, and molecular analyses from a single
paraffin-embedded sample has been limited. We have
therefore developed a new tissue stabilization technology
(PAXgene Tissue System), for simultaneous preservation
of nucleic acids, proteins, and morphological features, and
have tested it in comparison with current state-of-the-art
techniques: FFPE for routinemorphological diagnostics and
snap-freezing for molecular analyses. Kap et al16 recently
demonstrated that morphology and antigenicity are well
preserved in tissue samples treated with PAXgene fixative
and then paraffin-embedded (PFPE samples). Here, we
provide a detailed description of the development of this
new stabilization technology and its ability to preserve
biomolecules (and nucleic acids in particular).
Materials and Methods
High-Throughput Screening for Novel Fixatives
Fixatives and Compounds
First, commercially available fixatives described as for-
malin replacements for preservation of morphology, nu-
cleic acids, or both were tested for their ability to pre-
serve morphology and biomolecules. Additional fixatives
were selected based on reports indicating their use for
special pathology staining applications or for nucleic
acid preservation (Table 1). In addition, 1150 substances
and combinations of substances (including mono-, bi-,
tri-, and polyvalent alcohols, cross-linkers, soluble salts,
and buffers) were screened and classified for their prop-
erties to stabilize biomolecules in tissue samples. Finally,
a multitude of different alcohols and acids in a great
variety of compositions, combined with substances iden-
tified in the large screening program as biomolecule pre-
servatives, were tested for biomolecule and morphology
preservation. In all, more than 1500 single compounds
and combinations were tested.Rat Tissue Samples
Rats (rattus norvegicus) were bred, maintained, and
sacrificed at the Animal Research Facility of Dusseldorf
University (Universitätsklinikum Düsseldorf Tierversuch-
sanlage) in accordance with the German Protection of
Animals Act. Rats were raised until a weight of 500 g.
Equal parts of rat liver and kidney were dissected within
5 minutes post mortem, submerged into one of the pres-
ervation solutions from the screening program, and
stored at room temperature.
RNA Extraction and Gel Electrophoresis
After fixation and storage, rat liver samples of 10 to 15mg
each were used for RNA extraction using an RNeasy Mini
Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions and were eluted in 80 L of RNase-free
water. Gel electrophoresis was performed with 15 L of
eluate on 1% agarose gels under denaturing conditions,
and RNA was visualized by ethidium bromide staining.
H&E Staining
For evaluation of morphology preservation, rat kidney
samples with a maximum thickness of 4 mm were sub-
merged in a preservation solution for 24 hours and then
were processed manually or on a Leica TP1020 auto-
mated tissue processor (Leica, Wetzlar, Germany). Pro-
cessing was performed with 70%, 80%, 90%, and 99%
ethanol, followed by isopropanol, xylene, xylene mixed
1:1 with low-melting paraffin, infiltration, and embedding
in low-melting paraffin. Sections (2 m thick) were
stained for 2 minutes with Gill’s hematoxylin and for 30
seconds with eosin-phloxine, and then were mounted
with Entellan mounting medium (Merck, Darmstadt, Ger-
Table 1. Examples of Commercially Available or Published
Reagents Tested in the Screening Program
Reagent Vendor or composition
RNAlater Life Technologies, Carlsbad, CA
Michel’s Zeus Scientific, Raritan, NJ
HistoChoice Amresco Inc., Solon, OH
Prefer Anatech Ltd, Battle Creek, MI
Z5 Anatech Ltd, Battle Creek, MI
FineFIX Milestone, Bergamo, Italy
Hope DCS, Hamburg, Germany
RCL2 Alphelys, Plaisir, France
Streck Tissue Fixative Streck, Omaha, NE
PreservCyt Hologic, Bedford, MA
AquaPreserve MultiTarget Pharmaceuticals, Salt
Lake City, UT
RNAsecure Life Technologies, Carlsbad, CA
S.T.A.R. buffer Roche Molecular Biochemicals,
Penzberg, Germany
UMFix Sakura Finetek, Torrance, CA
Ethanol 70% ethanol p.a. (pro analysis)
Methacarn Methanol, chloroform, acetic acid
Carnoy’s fixative Ethanol, chloroform, acetic acid
Farmer’s Ethanol, acetic acid
Wolman’s solution Ethanol, acetic acid
Delaunay’s Acetone, ethanol, trichloroacetic acid
FAA Formalin, acetic acid, ethanol
FPA Formalin, acetic acid, propionic acid
Davidson’s fixative Formalin, ethanol, acetic acid, watermany) for microscopic analysis.
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Human malignant tissue specimens (eg, leiomyosarcoma,
cholangiocellular carcinoma, colorectal carcinoma) and
nonmalignant tissue specimens (eg, breast, stomach, liver,
intestine, kidney, spleen, adipose tissue) were divided into
equal aliquots and either snap-frozen in methyl butane
cooled by liquid nitrogen, fixed in buffered formaldehyde
(for 3 hours, 24 hours, and up to 120 hours), or fixed (for 3
hours, 24 hours, and up to 120 hours) in PAXgene Tissue
Fix (PreAnalytiX, Hombrechtikon, Switzerland) and then
transferred into PAXgene Tissue Stabilizer (for 24 hours
and up to 120 hours) at room temperature. After stepwise
dehydration in 70%, 80%, 90%, and 99% ethanol, fol-
lowed by isopropanol and xylene, the PAXgene Tissue-
fixed and formaldehyde-fixed samples were embedded
in low-melting paraffin and stored in the dark at 4°C and,
for some experiments, also at room temperature. All sam-
ples were processed using formalin-free reagents. Sec-
tions (2 m thick) were stained for 2 minutes with Gill’s
hematoxylin and for 30 seconds with eosin-phloxine, and
then were mounted with Entellan for microscopic
analysis.
All sample donors provided written informed consent,
and the study was approved by the Ethics Committee of
the Medical University of Graz, Austria (reference number
20-066). For miRNA and DNA analyses, human colon
cancer tissue samples were obtained from Cureline
(South San Francisco, CA).
All analyses were performed for research purposes
only.
Immunohistochemistry
For immunohistochemical assessment of PFPE samples,
sections (2 m thick) were cut and treated according to
protocols routinely used for immunohistochemical diag-
nosis of FFPE samples. For MLH1 (clone G168-15, mono-
clonal antibody, dilution 1:20; Biocare Medical, Concord,
CA), slides were pretreated for 40 minutes in a microwave
at 300 W with Dako target retrieval buffer (pH 9) (Dako,
Glostrup, Denmark). Immunohistochemistry was performed
on a Dako Autostainer Plus system with 60 minutes incuba-
tion of the antibody. Sections of snap-frozen samples
were fixed with 4% buffered formaldehyde at room
temperature, followed by methanol and acetone steps
for 5 minutes at 20°C. Pretreatment was done in a
microwave for 10 minutes at 300 W using Dako target
retrieval buffer (pH 9). Primary antibody was incubated
for 60 minutes at room temperature, and visualization
was performed with a Dako Real EnVision K5007 De-
tection System (DAKO). Slides were counterstained
with Mayer’s hematoxylin.
RNA Extraction, GAPDH Quantitative Real-Time
PCR Assay, and TaqMan Array Gene Signature
Plate
For RNA extraction, 10 to 20 sections (5 m thick) from
snap-frozen, PFPE, or FFPE human tissue samples werecut on a cryotome (Leica CM3050-1-1-1) or a microtome
(HM350; Microm International, Walldorf, Germany). The
paraffin-embedded samples were deparaffinized by xy-
lene and ethanol steps.
RNA was extracted according to the manufacturer’s in-
structions using a PAXgene Tissue RNA Kit (PreAnalytiX,
Hombrechtikon, Switzerland) for PFPE, an RNeasy
FFPE Kit (Qiagen) for FFPE samples, or the Invitrogen
TRIzol procedure (Life Technologies, Darmstadt, Ger-
many) for snap-frozen samples. RNA was eluted in a
final volume of 40 L of kit buffer or RNase-free water
and stored at 70°C.
RNA concentration and purity were determined using a
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies-Thermo Fisher Scientific, Wilmington, DE).
Electropherograms were obtained using an Agilent 2100
Bioanalyzer platform (Agilent Technologies, Santa Clara,
CA) with an Agilent RNA 6000 Nano Kit; Agilent 2100
Expert software version B.02.03.SI307 was used to cal-
culate the RNA integrity number.
From each sample, 1 g of RNA was transcribed into
cDNA using High-Capacity cDNA Reverse Transcription
Kit (Life Technologies-Applied Biosystems, Foster City,
CA) according to the manufacturer’s instructions. After
reverse transcription, cDNA was stored at 20°C.
Five microliters of 1:20 cDNA dilutions served as tem-
plate for PCR using Power SYBR Green PCR Master Mix
(Life Technologies-Applied Biosystems). For the amplifica-
tion of fragments of human GAPDH, the following primers
were used: GAPDH forward 5=-CCACATCGCTCAGACAC-
CAT-3=; GAPDH reverse 71 bp 5=-ACCAGGCGCCC-
AATACG-3=; 153 bp 5=-GTAAACCATGTAGTTGAGGTC-3=;
200 bp 5=-TTGACGGTGCCATGGAATTT-3=; 277 bp 5=-
ACTTGATTTTGGAGGGATCT-3=; 323 bp 5=-AAGACGC-
CAGTGGACTCCA-3=; and 530 bp 5=-ACGATACCAAAGT-
TGTCATG-3=. All samples and controls were analyzed in
triplicate for 45 cycles of PCR using aMicroAmp fast 96-well
reaction plate format on an ABI 7900 Real-Time PCR Sys-
tem (Life Technologies-Applied Biosystems). Results were
analyzed using ABI SDS software version 2.3. Nonspecific
products were excluded by melting curve analysis, and
median CT values were used for further data analysis. Se-
lected PCR products were separated on a 2% agarose gel
and visualized by ethidium bromide.
For analysis of cancer gene signature, 2 g of RNA
from PFPE, FFPE, and snap-frozen human liver samples
was transcribed into cDNA using the High-Capacity
cDNA Reverse Transcription Kit (Life Technologies-Ap-
plied Biosystems) according to the manufacturer’s in-
structions. Next, 10 L of TaqMan gene expression mas-
ter mix was added to 10 L of cDNA, leading to a final
concentration of 20 ng per 20-L reaction. Samples were
analyzed on an ABI 7900 Real-Time PCR System using
the preconfigured TaqMan Array 96-Well Plate Human
Molecular Mechanisms of Cancer including 92 pathway-
associated genes and 4 endogenous control genes (all
from Life Technologies-Applied Biosystems). Results
were analyzed using ABI SDS software. The coefficient of
determination (R2) was calculated as the square of Pear-
son’s correlation coefficient (r).
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miRNAs from corresponding aliquots of three colon can-
cer cases were analyzed. RNA was isolated in each case
from three sections (10 m thick) using a PAXgene Tis-
sue miRNA Kit for PFPE tissue and a Recover All Total
Nucleic Acid Isolation Kit for FFPE (Life Technologies-
Applied Biosystems, Austin, TX) for FFPE tissue, accord-
ing to the manufacturer’s instructions. RNA was eluted
with 40 L (PFPE tissues) or 60 L (FFPE tissues) of the
respective kit elution buffer. RNA from the corresponding
snap-frozen sample was isolated from 10 mg of tissue
with a miRNeasy Mini Kit (Qiagen) using the TissueLyser
II system (Qiagen) for tissue disruption, and then was
eluted in 80 L of elution kit buffer. RNA was quantified
with a NanoDrop ND-1000 spectrophotometer. RNA in-
tegrity was measured with an RNA 6000 Nano Chip Kit on
an Agilent 2100 Bioanalyzer platform.
Small noncoding RNA species were quantified with
real-time PCR on an ABI Prism 7700 sequence detection
system, and miRNAs 10a, 16, 29a, 30b, 103, and 192
were amplified using the TaqMan Micro RNA Reverse
Transcription Kit and TaqMan miRNA assays (Life Tech-
nologies-Applied Biosystems, Carlsbad, CA) with prefor-
mulated primer and probe sets. Reverse transcription
was performed with 5 ng total RNA in a 15-L reverse
transcription reaction mix; 1 L from the reaction was used
for quantitative PCR. In addition, expression of miRNAs 9,
10a, 10b, 29a, 103, 125b, 143, 145, 155, and 192 and
expression analyses of small nucleolar and nuclear RNAs
RNU1A, RNU5A, RNU6B, SNORD25, SCARNA17, and
SNORA73A were performed with a Qiagen miScript Re-
verse Transkription Kit, in combination with miScript
Primer Assay and a Qiagen QuantiTect SYBR Green PCR
Kit. Using miScript assays, reverse transcription was per-
Figure 1. Examples of typical compound screening results for RNA and m
Commercially available or published fixatives. B: Compound screening (all p
with substances from the large screening program. D: Two-step fixation and stab
paraffin-embedded rat kidney fixed for 24 hours with selected other fixatives or PAformed with 200 ng total RNA in 20-L reverse transcrip-
tion reaction mixes; 2 L from the reaction was used for
quantitative PCR. Mean CT values (SD) were obtained
from three independent RNA extractions per sample and
were analyzed in duplicate. For each miRNA, the coeffi-
cient of determination (R2) between FFPE or PFPE and
the corresponding snap-frozen sample was calculated.
DNA Extraction, Long-Range and Multiplex
PCR, and Pyrosequencing
DNA from paraffin-embedded tissue was isolated in each
case from three sections (10 m thick) using a PAXgene
Tissue DNA Kit (PreAnalytiX) for PFPE tissue and a
QIAamp DNA FFPE Tissue Kit (Qiagen) for FFPE tissue.
DNA was eluted in 40 L of the respective kit elution
buffer. DNA was isolated from 10 mg of snap-frozen
tissue with a QIAamp DNA Mini Kit (Qiagen), using a
TissueLyser II system (Qiagen) for tissue disruption, and
then was eluted in 60 L of elution kit buffer. DNA quan-
tification was performed with a NanoDrop ND-1000
spectrophotometer.
Three hundred nanograms of each DNA type and the
Lambda HindIII-Marker DNA (New England Biolabs, Frank-
furt, Germany) were run on 1% Tris/borate/EDTA buffered
agarose gels and visualized with ethidium bromide. Long-
range PCR was performed with 100 ng DNA and 45 cycles
using a Qiagen LongRange PCR Kit. Primers 33093F and
38185R were used for amplification of a 5093-bp fragment
of human tuberous sclerosis complex.17 PCR products
were separated on 1% Tris/acetate/EDTA buffered agarose
gels with a marker GelPilot 1 kb Plus ladder (Qiagen). For
multiplex PCR, 10 ng DNA was amplified in 35 cycles with
a Multiplex PCR Kit (Qiagen). Eight fragments of human
genes were amplified: 222 bp of prion protein (PRNP; forward
gy preservation, using RNA from rat liver on formaldehyde agarose gels. A:
es are volume per volume). C: Combinations of different alcohols and acidsorpholo
ercentagilization with the PAXgene tissue stabilization system. E: H&E staining of
Xgene fixative. Original magnification, 400. Scale bar  50 m.
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GCCAGAGGTATCCAGGC AA-3=), 310 bp of immunoglob-
ulin-associated  protein (CD79b; forward 5=-CCTATCTTC-
CTGCTGCTGGACAA-3=, reverse 5=-GGAGAGGGATG-
GAGATCAGAGTGTTA-3=), 414 bp of Hardy-Zuckerman 4
feline sarcoma viral oncogene homolog (c-KIT; forward 5=-
GCCGACAAAAGGAGATCTGTGAGAA-3=, reverse 5=-GGC-
AATGACATACCAAAGGCTGGTA-3=), 523 bp of angioten-
sin II receptor, type 2 (AGTR2; forward 5=-TCTTCAAC-
CTCGCTGTGGCTGA-3=, reverse 5=-ATCTTCAGGACTTG-
GTCACGGGTT-3=), 662 bp of CD14 molecule (CD14;
forward 5=-TGTCTGCAGTAGAGGTGGAGATCCAT-3=, re-
verse 5=-GCATCTCGGAGCGCTAGGGTTT-3=), 756 bp of
CD40 molecule (CD40; forward 5=-TGCCATCCTCTTGGT-
GCTGGTCT-3=, reverse 5=-CAGCAGTGTTGGAGCCAG-
GAAGAT-3=), 845 bp of CD59 molecule (CD59; forward
5=-GCTTGAGCAACCTGGCTAAGATAGAGG-3=, reverse
5=-GAGTTAGCAGGAGGCTGGATGCAGATG-3=), and 955
bp of CD19 molecule gene (CD19; forward 5=-TTTCCA-
GACTTCCTGAGCCCTCAT-3=, reverse 5=-GCATACAG-
GATTCCTCTCATATCCTCAT-3=). PCR products were sep-
arated on 2% Tris/acetate/EDTA buffered agarose gels with
a marker GelPilot midrange ladder (Qiagen).
For pyrosequencing, 1.3 to 14.3 ng of DNA from cor-
responding PFPE and FFPE samples from five human
colon cancer cases was amplified on an ABI 9700 ther-
mal cycler (Life Technologies-Applied Biosystems) with
primers targeting codons 12/13 of the human KRAS geneor codon 600 of the human BRAF gene. Amplicons were
immobilized on streptavidin-Sepharose (GE Healthcare,
Piscataway, NJ) beads and sequenced on a PyroMark
Q24 MDx instrument using PCR and the sequencing
primer provided with the TheraScreen KRAS and Ther-
aScreen BRAF pyrosequencing kits (all from Qiagen),
according to the manufacturer’s instructions.
Protein Extraction and Western Blot
Nonmalignant human liver tissues were divided into four
aliquots and snap-frozen, fixed with PAXgene fixative (3
or 24 hours fixation time, each followed by 24 hours of
stabilization) and paraffin-embedded, or formalin-fixed
(for 24 hours) and paraffin-embedded. Proteins from
PFPE and snap-frozen tissues were extracted according
to the Qproteome FFPE Tissue Kit (Qiagen) protocol with
some modifications. Briefly, after standardized deparaf-
fination of tissue sections (10 m thick) in xylene and
rehydration in graded alcohol series, the tissues were
scratched from unstained slides using a needle, trans-
ferred into extraction buffer, and incubated for 15 minutes
on ice, followed by heating at 70°C for 2 hours with
agitation. Proteins from FFPE tissues were extracted ac-
cording to the Qproteome FFPE Tissue Kit protocol.
Equal amounts (20 g) of protein lysates were separated
on one-dimensional SDS-PAGE gels and transferred onto
nitrocellulose membrane. Immunoblotting was performed
Figure 2. Preservation of morphology and anti-
genicity. A–D: Corresponding human tissue sam-
ples were either fixed in neutral-buffered form-
aldehyde for 24 hours (FFPE 24h), PAXgene
fixative for 24 hours followed by PAXgene tissue
stabilizer for 24 hours (PFPE 24h), or snap-frozen
in liquid nitrogen (CRYO). In H&E staining of
tissue from human stomach (antrum) (A), ileum
(B), and (C) rectum, PFPE samples show well-
preserved morphology, similar to FFPE samples,
whereas in cryopreserved samples the morphol-
ogy (eg, chromatin structure) is less well pre-
served. D: Immunohistochemical analysis of
MLH1, a typical screening marker routinely used
for hereditary colon cancer. Cancer and non-
neoplastic colon tissue are represented on the
slides, both positive for MLH1. The staining pat-
tern is similar in FFPE, PFPE, and frozen samples.
Original magnification: 400 (A and B); 200
(C and D). Scale bars: 50 m (A and B);100 m
(C and D).
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Akt, anti-p-GSK3, anti-GSK3, anti-p-PTEN, anti-PTEN,
anti-cytokeratin 18 (all from Cell Signaling Technology,
Frankfurt, Germany), anti-vimentin (Dako), anti-GAPDH
(Enzo Life Sciences, Lörrach, Germany), and anti--actin
(Sigma-Aldrich, Steinheim, Germany). The proteins were
visualized using Amersham ECL Plus detection reagent
(GE Healthcare Europe, Freiburg, Germany).
Results
In total, more than 1500 single compounds and combi-
nations were tested for simultaneous preservation of mor-
phology and RNA in tissues by using a high-throughput
screening approach. First, we investigated the ability of
Figure 3. RNA preservation and gene expression. A: Representative resu
electropherogram of RNA from FFPE tissue shows strongly degraded RNA. F
peaks are clearly visible, but lower and shorter fragments are increased, com
shows distinct peaks corresponding to ribosomal 18S and 28S RNA. B: Gel el
amplified from human nonmalignant liver tissue. C: Summary of CT values
(71 to 530 bp). Human malignant and nonmalignant tissue samples (n 45) f
were analyzed in comparison with the corresponding snap-frozen samples. E
and 4 endogenous control genes (18S, GAPDH, GUSB, and HPRT1). The ge
by qRT-PCR on a TaqMan array plate preconfigured for human molecular mechanism
sample as reference. RIN, RNA integrity number (scored from 1 to 10, with higher vcommercially available fixatives and fixatives described
in publications as formalin replacements (Table 1) to
preserve biomolecules, morphology, or both (Figure 1, A
and E). The results obtained served as benchmark for
further screening and subsequent classification of 1150
single substances and combinations (including mono-,
bi-, tri-, and polyvalent alcohols, cross-linkers, soluble
salts, and buffers) for their ability to stabilize RNA in
tissue samples (Figure 1, B and E). Next, various alcohols
and acids in a great variety of compositions, combined
with substances identified in the large screening program
as good biomolecule preservatives (Figure 1C), were
tested for their ability to preserve histological features.
Although formulations containing cross-linking re-
agents tended to preserve morphology appropriately, we
RNA integrity determined on an Agilent Bioanalyzer 2100 platform. The
tissue (fixed for 3 or 24 hours, followed by 24 hours stabilization), the rRNA
ith frozen samples. RNA extracted from snap-frozen (CRYO) liver samples
oresis of qRT-PCR products for different amplicon lengths of human GAPDH
than 800 qRT-PCR assays, based on different amplicon lengths of GAPDH
erent organs, fixed for 3 to 120 hours with PAXgene fixative or formaldehyde,
indicateSD. D: Gene expression analysis of 92 cancer pathway-associated
ture from PFPE, FFPE, and snap-frozen (CRYO) human liver was analyzedlts for
or PFPE
pared w
ectroph
for more
rom diff
rror bars
ne signas of cancer. Genes are sorted by increasing CT value, using the snap-frozen
alues indicating greater RNA integrity).
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formance of nucleic acids in downstream applications
such as PCR, even if low concentrations or reversible
cross-linkers were used. On the other hand, alcohols
(pure or in mixtures) and dehydrating reagents at high
concentrations performed well for preserving biomol-
ecules, but compromised overall morphology. Some re-
agents, such as 70% ethanol, preserved morphology in
some tissue types (eg, rat intestine) but produced clear
shrinkage artifacts in others (eg, rat kidney). Rat kidney
was found to be most sensitive to shrinkage, whereas
RNA from rat liver was especially prone to RNA degra-
dation caused by inferior fixatives; these two were there-
fore chosen as the main tissues for screening. Prevention
of morphological artifacts such as shrinkage and biomol-
ecule degradation could be achieved only with a balanced
formulation of alcohols at optimized concentrations and the
addition of acids in combination with a soluble organic
compound identified in the screening program.
The combination of alcohols, an acid, and a soluble
organic compound that best fulfilled the screening crite-
ria was further optimized by determining the best con-
centration range for each component. The resulting new
tissue stabilization procedure, the PAXgene Tissue Sys-
tem, uses two reagents: a fixation reagent that efficiently
penetrates tissues and a stabilization reagent consisting
of a mixture of different alcohols that stops the fixation
process and stabilizes the sample for storage or trans-
port until further processing and paraffin embedding
(Figure 1, D and E). For optimal performance, reagents
used for processing and paraffin embedding have to be
free of cross-linking agents such as formalin.
This novel tissue stabilization technology was then
comprehensively evaluated and compared with current
state-of-the-art techniques for routine morphological di-
agnostics and molecular analyses, using matched pairs
of snap-frozen, FFPE, and PFPE tissue samples.
PFPE tissues from different organs revealed very good
preservation of morphology and antigenicity, similar to
that of the corresponding FFPE tissues (Figure 2; see also
Supplemental Figure S1 at http://jmd.amjpathol.org),
which is in accord with results recently reported by Kap
et al.16 There was a tendency for some antigens to re-
quire less harsh retrieval treatments for immunohisto-
chemistry, compared with FFPE tissues, which is consis-
tent with the absence of cross-linking activity in the
PAXgene tissue stabilization system (data not shown).
Importantly, the preservation of mRNA in PFPE tissues
was similar to that in snap-frozen tissues, and greatly
exceeded the quality from FFPE samples (Figure 3A).
Comparison of snap-frozen with PFPE tissues showed
similar amounts of RNA recovered. Furthermore, ampli-
con lengths obtained by quantitative RT-PCR (qRT-PCR)
demonstrated similar reaction efficacy for both small (71
bp) and large (530 bp) amplicons (Figure 3B). In con-
trast, FFPE tissues showed consistently higher CT values
(4 to 15 cycles higher, depending on the amplicon
length), compared with the CT value for the correspond-
ing snap-frozen tissue (Figure 3C). Additionally, fixation
with the PAXgene tissue system was not sensitive to over-
or underfixation, because no adverse effect on mRNAquality was observed after either a prolonged fixation period
(up to 120 hours) or a short fixation period (3 hours). This
excellent preservation of mRNA by the PAXgene tissue
stabilization system was demonstrated in more than 800
qRT-PCR analyses of different tissues representing a va-
riety of fixation conditions (Figure 3C). Furthermore, com-
parative analysis of 92 cancer pathway-associated
genes showed a strong correlation of the gene signature
from PFPE and snap-frozen tissue (R2  0.99). In con-
trast, results from FFPE tissue showed not only lower am-
plification efficacy, but also major gene-to-gene variations
(up to seven cycles), compared with the corresponding
snap-frozen samples (R2  0.89) (Figure 3D).
Comparative studies of miRNA preservation and re-
covery revealed a strong correlation of miRNA expres-
sion between PFPE tissues and snap-frozen samples
(R2  0.95), whereas for FFPE samples a lower correla-
tion (R2  0.81) was observed (Figure 4).
DNA isolated from PFPE tissues was of similar molec-
ular mass as DNA isolated from snap-frozen tissues, and
the DNA was well suited for long-range and multiplex
PCR (Figure 5), as well as for Sanger sequencing (data
not shown) and pyrosequencing reactions (see Supple-
mental Figure S2 at http://jmd.amjpathol.org). In contrast,
Figure 4. Correlation of miRNA expression between PFPE, FFPE, and snap-
frozen samples. miRNAs from corresponding aliquots of three colon cancer
cases were quantified by qRT-PCR on a TaqMan ABI Prism 7700 sequence
detection system. miRNAs 10a, 16, 29a, 30b, 103, and 192 were amplified
using TaqMan miRNA assays. Additionally, expression analyses of miRNAs 9,
10a, 10b, 29a, 103, 125b, 143, 145, 155, and 192 and expression analyses
of small nucleolar and nuclear RNAs RNU1A, RNU5A, RNU6B, SNORD25,
SCARNA17, and SNORA73A were performed with a miScript Reverse Tran-
scription Kit in combination with miScript primer assays and a QuantiTect
SYBR Green PCR Kit (Qiagen). Mean CT values of PFPE samples highly
correlated with snap-frozen samples, whereas FFPE samples showed a lower
correlation. Error bars indicate SD.
Stabilization of Biomolecules 465
JMD September 2012, Vol. 14, No. 5corresponding samples of FFPE tissues did not allow
recovery of large DNA molecules (Figure 5).
In addition to nucleic acids, full-length proteins can
also be isolated from PFPE tissues. The isolated proteins
were suitable for a variety of protein analysis techniques,
including Western blotting, reverse-phase protein arrays,
and matrix-assisted laser desorption/ionization (MALDI)-
imaging mass spectrometry.18 Proteins extracted from
PFPE tissues maintained their molar ratios and revealed
good preservation of several phosphorylated sites, an
important prerequisite for the analysis of activated sig-
naling pathways (Figure 6).19–22 In contrast, the extraction
of certain proteins from FFPE tissues was less efficient (eg,
lower recovery of vimentin), and the preservation of some
phosphorylated sites was different (eg, lower amounts of
p-NFkB, p-Akt) in FFPE tissues, compared with correspond-
ing snap-frozen tissues (Figure 6).
Discussion
The PAXgene tissue stabilization system is not intended to
be a general formaldehyde replacement, but it should fa-
cilitate analysis of disease conditions in which collection of
frozen tissue for molecular analyses is difficult or not feasible.
Consistent with previous studies, our RT-PCR analysis
of FFPE samples resulted in increased raw CT values,
compared with corresponding snap-frozen samples. Fur-
thermore, we observed up to 128-fold differences in qRT-
PCR efficacy of FFPE samples, depending on the mRNA
sequence, which may cause major problems in compar-
ing expression levels of different genes.23,24 These vari-
ations and differences were avoided by PAXgene fixa-
tion. Comprehensive studies using a series of different
Figure 5. DNA integrity and performance in long-range and multiplex PCR.
A:Genomic DNA extracted from corresponding FFPE, PFPE, and snap-frozen
(CRYO) samples from five human colorectal cancer cases was separated on
1% agarose gels and visualized with ethidium bromide. B: Long-range PCR
was performed using a Qiagen kit. Primers 33093F and 38185R were used for
amplification of a 5093-bp fragment of human tuberous sclerosis complex. PCR
products were separated on 1% agarose gels with a marker GelPilot 1 kb Plus
ladder (Qiagen). C: Multiplex PCR of eight fragments of different human genes:
prion protein (PRNP, 222 bp), immunoglobulin-associated  protein (CD79b,
310 bp), Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (c-KIT,
414 bp), angiotensin II receptor, type 2 (AGTR2, 523 bp), CD14molecule (CD14,
662 bp), CD40 molecule (CD40, 756 bp), CD59 molecule (CD59, 845 bp), and
CD19 molecule gene (CD19, 955 bp). PCR products were separated on 2%
agarose gels with a marker GelPilot midrange ladder (Qiagen).analytical techniques demonstrated that RNA quality andreliability of gene expression data were similar in PFPE
and snap-frozen samples. Because the manufacturers’
recommended fixation times ranged from 3 hours to a
maximum of 24 hours, these conditions were used mainly
to evaluate the preservation of morphology and biomol-
ecules. In addition, we were particularly interested in the
robustness of the new fixation technique in a routine
clinical setting, where a broader range of fixation times
may occur. We chose RNA as one of the most sensitive
analytes. Fixation and stabilization times of up to 120
hours had no major effect on RNA quality and subse-
quent PCR analysis (Figures 1D and 3C). Conclusively,
fixation over the weekend (up to 72 hours) and stabiliza-
tion for up to 1 week at room temperature for storage or
transport seems feasible without compromising the qual-
ity of RNA-based molecular analyses.
The excellent preservation of RNA, high molecular
weight DNA, and phosphoproteins, in combination with
the good morphological quality of histological sections,
are the major strengths of the new fixation technique. The
high-throughput screening approach used for the develop-
ment of PAXgene fixation allowed testing most of the cur-
rently known fixatives, and demonstrated that the favorable
properties rely on the optimized ratios of its compounds.
Because any change in the concentrations or chemical
nature of the compounds, or even minor contaminations
with formalin, had clear negative effects, we consider for-
mulation of the PAXgene Tissue System to be optimized.
Figure 6. Western blot analysis of protein preservation. Proteins were extracted
from corresponding snap-frozen (CRYO), PFPE (fixed for 3 or 24 hours, fol-
lowed by 24 hours stabilization), and FFPE (fixed for 24 hours) human liver
samples. Equal amounts (20 g) of protein lysates were separated by one-
dimensional SDS-PAGE and transferred onto nitrocellulose membrane. Immu-
noblotting was performed using anti-p-NFkB p65, anti-NFkB p65, anti-p-Akt,
anti-Akt, anti-p-GSK3, anti-GSK3, anti-p-PTEN, anti-PTEN, anti-cytokeratin 18,
anti-vimentin, anti-GAPDH, and anti--actin antibodies.
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JMD September 2012, Vol. 14, No. 5The favorable properties of the PAXgene tissue sta-
bilization system demonstrated in the present study
open the opportunity for analysis of a broad spectrum
of biomolecules from the same tissue samples as col-
lected for histopathological diagnosis. This minimizes
the risk that molecular analyses negatively interfere
with routine health care, and guarantees that molecular
data can be directly compared with histopathologically
characterized lesions. This PAXgene technology will
markedly facilitate investigation of molecular altera-
tions in tissues that are notoriously difficult to collect in
a routine health care setting. Complex sampling and
preservation procedures such as processing human
tissue samples according to different protocols, and
particularly snap-freezing in liquid nitrogen, are diffi-
cult to implement (especially in the operating room),
are error-prone, and are a major cause of protocol
infringement in clinical trials. The tissue stabilization
technology we have developed and tested might there-
fore substantially contribute to the advancement of
medical research in general, as well as to the devel-
opment of nucleic acid-based biomarkers.25–27
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